Based on the Omnicell Inc stock forecast from 5 analysts, the average analyst target price for Omnicell Inc is USD 41.67 over the next 12 months. Omnicell Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Omnicell Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Omnicell Inc’s stock price was USD 43.20. Omnicell Inc’s stock price has changed by -4.45% over the past week, -5.45% over the past month and +10.15% over the last year.
No recent analyst target price found for Omnicell Inc
No recent average analyst rating found for Omnicell Inc
Company Overview Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. Read Less
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patien...Read More
Frequently Asked Questions About Omnicell Inc (OMCL) Stock
Based on ratings from 5 analysts Omnicell Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on OMCL's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for OMCL is USD 41.67 over the next 12 months. The maximum analyst target price is USD 54 while the minimum anlayst target price is USD 30.
OMCL stock's Price/Earning ratio is 470.14.
Our analysis grades OMCL stock's Price / Earning ratio at F. This means that OMCL stock's Price/Earning ratio is above 92% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this OMCL may be a overvalued for its sector.
The last closing price of OMCL's stock was USD 43.20.
The most recent market capitalization for OMCL is USD 2.13B.
Based on targets from 5 analysts, the average taret price for OMCL is projected at USD 41.67 over the next 12 months.
This means that OMCL's stock price may go down by -3.55% over the next 12 months.
We can't find any ETFs which contains Omnicell Inc's stock.
As per our most recent records Omnicell Inc has 3,660 Employees.
Omnicell Inc's registered address is 4220 North Freeway, Fort Worth, TX, United States, 76137.
You can get more information about it from Omnicell Inc's website at https://www.omnicell.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Omnicell Inc (OMCL) Stock
Based on ratings from 5 analysts Omnicell Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on OMCL's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for OMCL is USD 41.67 over the next 12 months. The maximum analyst target price is USD 54 while the minimum anlayst target price is USD 30.
OMCL stock's Price/Earning ratio is 470.14.
Our analysis grades OMCL stock's Price / Earning ratio at F. This means that OMCL stock's Price/Earning ratio is above 92% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this OMCL may be a overvalued for its sector.
The last closing price of OMCL's stock was USD 43.20.
The most recent market capitalization for OMCL is USD 2.13B.
Based on targets from 5 analysts, the average taret price for OMCL is projected at USD 41.67 over the next 12 months.
This means that OMCL's stock price may go down by -3.55% over the next 12 months.
We can't find any ETFs which contains Omnicell Inc's stock.
As per our most recent records Omnicell Inc has 3,660 Employees.
Omnicell Inc's registered address is 4220 North Freeway, Fort Worth, TX, United States, 76137.
You can get more information about it from Omnicell Inc's website at https://www.omnicell.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for OMCL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
